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leiomyomas. Following the injection, the patient developed diffuse red-
ness and itching, improving with oral prednisone, but subsequently
worsening with diffuse erythema, hyperpigmented macules, increased
scaling, and desquamation. Skin biopsies showed ﬁndings consistent
with drug reaction with eosinophilia and systemic symptoms
(DRESS). The Registry of Severe Cutaneous Adverse Reactions
(RegiSCAR) inclusion criteria for DRESS syndrome include acute rash,
fever N38 °C, internal organ involvement like transaminitis, lymphope-
nia, thrombocytopenia with eosinophilia, and negative investigative
results supporting alternative.
The patient underwent repeat imaging studies, showing further in-sion to proceedwith surgical removal of themass. However, prior to the1. Introduction
Hemophagocytic lymphohistiocytosis is a pathologic
hyperinﬂammatory syndrome resulting from over-activation of
CD8+ cytotoxic T-lymphocytes (CTL's) and benign macrophages with
marked release of inﬂammatory cytokines, ultimately resulting in tissue
invasion of the liver, spleen, and/or lymph nodes. Primary HLH is a ge-
netic disorder arising from defects in the cytotoxic pathway whereas,
secondary HLH may arise in the background of various disorders, in-
cluding infection, malignancy, rheumatory disease, or metabolic condi-
tions. Secondary HLH has been reported as a paraneoplastic syndrome,
predominantly in hematolymphoidmalignancies, and is rarely associat-
ed with non-hematolymphoid neoplasms. In this report, we describe a
case of HLH associated with an ovarian dysgerminoma, which to the
best of our knowledge represents the ﬁrst such case in the reported
literature.
2. Case report
A 41-year-old women (gravida 1, para 1) presented with a progres-
sively enlarging pelvic mass and menorrhagia. Imaging studies sug-
gested the presence of uterine leiomyomata. Depot Lupron injections⁎ Corresponding author at: Stanford School of Medicine, Department of Obstetrics and
Gynecology, Division of Gynecologic Oncology, 300 Pasteur Drive, HG332, Stanford, CA
94305-5317, United States.
E-mail address: odorigo@stanford.edu (O. Dorigo).
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2352-5789/© 2016 The Authors. Published by Elsevier Inc. This is an open access article undercrease in the size of the pelvic mass. These ﬁndings prompted the deci-
planned surgery, the patient developed fever and tachycardia, requiring
admission to the hospital for systemic inﬂammatory response syn-
drome (SIRS). Laboratory testing revealed signiﬁcant abnormalities,
including neutropenia (WBC = 0.8 [4.0–11.0 K/μL]), low absolute neu-
trophil count (ANC = 0.05 [1.7–6.7 K/μL]), anemia (hemoglobin =
10.3 [11.7–15.7 g/dL]), elevated liver enzymes (AST = 173 [b40 U/L]);
ALT = 253 [b80 U/L]); elevated alkaline phosphatase = 1889
[b130 U/L]), hypoalbuminemia (albumin = 1.9 [3.5–5.0 g/dL]),
hypertriglyceridemia (triglycerides = 310 mg/dL [b150 mg/dL]), ele-
vated D-dimer = 2971 [b451 ng/mL], and elevated ferritin = 1459
[5–114 ng/mL] (Fig. 3).
Based on the clinical and initial laboratory ﬁndings, the diagnosis
of HLH was considered since the patient met diagnostic criteria
(fever N38.5 °C for N7 days, ﬁbrinogen b150 mg/dL, and serum ferri-
tin N500 ng/L). Elevated soluble IL-2 receptor levels of 8919 [45–
1105 μ/mL] further supported the diagnosis of HLH. Additional workup
included a liver biopsy, showingmultifocal hepatocellular necrosis with
increased sinusoidal and portal macrophages. Bone marrow biopsy and
aspirate showed a cellular marrow with normal trilineage, maturating
hematopoiesis. In addition, marked hemophagocytosis was noted
with numerous enlarged histiocytes containing engulfed mature and
nucleated red blood cells, platelets, and occasional polymorphonuclear
(PMN) cells (Fig. 1). Serologies for Epstein-Barr virus, human herpes
virus-6, antibody antinuclear antibody, anti-smooth muscle antibody,
and viral hepatitis were negative.
In an attempt to increase the ANC, the patient received the granulo-
cyte colony-stimulating factor analog ﬁlgrastim. However, despite
14 days of continuous administration of ﬁlgrastim, the ANC failed tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Bone marrow aspirates demonstrating histiocytes with intracellular nucleated red blood cell (A, arrow) or intracellular neutrophil (B, arrow).
Fig. 2. Ovarian dysgerminoma on gross examination with a tan-yellow cut surface with
central necrosis and hemorrhage (A) and on microscopic examination showing nests of
large, uniform cells with prominent nucleoli and abundant pale to clear cytoplasm,
separated by ﬁbrous septa (B).
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ic resonance imaging revealed a large solid abdominal-pelvic mass like-
ly arising from the left ovary. Follow-up computerized tomography (CT)
scan of the abdomen and pelvis demonstrated a well-circumscribed
heterogeneous abdominalmassmeasuring 19× 12 cmwithmass-effect
on the surrounding structures, splenomegaly up to 16 cm, right paren-
chymal and aortopulmonary lymph nodes measuring 1.4 cm and
1.1 cm, respectively. A ﬁne needle aspiration of the pelvic mass was
performed. The pathology showed a malignant germ cell tumor.
Serum markers including LDH = 1891 [b340 U/L], CA-125 = 188
[b35 U/mL], beta-hCG = 5 [b5 mIU/mL], HE4 = 134 [b70 pmol/L],
and AFP = 4 [b10 ng/mL] were supportive of the diagnosis of a germ
cell tumor.
The patient's laboratory values at that timewere signiﬁcant forWBC
0.4 K/μL, ANC b 0.02 K/μL, hemoglobin 8.3 g/dL, platelets 115 K/μl,
AST 382 U/L, ALT 304 U/L, alkaline phosphatase 1813 U/L, albumin
1.6 g/dL, and D-dimer 9954 ng/ml (Fig. 3). Given the presence of an
ovarianmalignancy, the decisionwasmade to proceedwith surgical re-
section of the adnexal mass despite the presence of severe immunosup-
pression and anticipated high perioperative infectious risk. The patient
underwent an exploratory laparotomy, which revealed a large mass
from the left ovary, without evidence of disease outside of the ovary.
No enlarged lymph nodes were appreciated throughout the abdomen
and pelvis. A left salpingo-oophorectomy was performed, but staging
was omitted in an attempt to limit the length of surgery and surgical
complications. The ﬁnal pathology showed a dysgerminoma,measuring
19.5 cm in greatest dimension (Fig. 2). Immunohistochemical stains
demonstrated positive staining for SALL4, OCT3/4, and CD117,
supporting the morphologic diagnosis of dysgerminoma. Pelvic wash-
ings contained suspicious cells and the left fallopian tube showed endo-
metriosis. The patient recoveredwell from surgerywithout postsurgical
complications. Following surgery, the patient's laboratory tests normal-
ized: (WBC = 5.4 K/μL post-operative day #14 (POD #14), ANC =
4.24 K/μL (POD#28), and platelets=173K/μL (POD#1) (Fig. 3). She re-
ceived four cycles of bleomycin, etoposide, and cisplatin (BEP) for adju-
vant therapy of stage IC dysgerminoma. The patient was without any
evidence of disease or symptoms of HLH at the last follow-up visit
24 months after diagnosis.
3. Discussion
To the best of our knowledge, this case represents the ﬁrst reported
secondary HLH in associationwith amalignant ovarian germ cell tumor.
Hematolymphoid malignancies, particularly T-cell and natural killer
(NK) cell lymphomas, are much more commonly associated with HLH,
compared to any solid tumors. The exact incidence of secondary HLHis largely unknown. However, a single-institution retrospective analysis
of malignancy-associated acquired HLH estimated the rate to be 0.36/
100,000/year (Machaczka et al., 2011). Only 3% of all HLH-associated
neoplasms are solid tumors, including hepatocellular carcinoma, small
cell lung cancer, prostate cancer, and mediastinal germ cell tumors
(Rosado and Kim, 2013). Early recognition of HLH is critical, since pa-
tients can develop severe pancytopenia and life-threatening infections
due to immunosuppression. HLH has a high mortality rate ranging
Fig. 3. Laboratory values.
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patients typically present with symptoms that are more commonly
associated with SIRS (including pyrexia of undetermined origin, tachy-
cardia, and leukopenia), disseminated intravascular coagulation (DIC),
and organomegaly (splenomegaly, hepatomegaly) (Lehmberg and Ehl,
2012). HLH patients may also present with hepatic dysfunction or neu-
rological deﬁcits. Furthermore, the broad symptoms of HLH can present
with mild manifestations and interval exacerbations.
HLH is described as a multisystem inﬂammatory process from ex-
cessive and persistent activation of antigen presenting cells, macro-
phages, histiocytes, CD8+ T cells, and overt proliferation and
abnormal migration of T cells (Filipovich, 2009). In HLH, NK cell
function is impaired, but the absolute quantity can be unaffected,
as seen in this patient with HLH and normal laboratory levels of NKcells (George, 2014). The most common ﬁnding in patients with
HLH includes prolonged fevers, likely due to cytotoxic T lymphocytes
and NK-mediated hypercytokinemia, rather than a direct result of an
infectious agent (Price et al., 2014). Such fevers typically do not
resolve despite the use of empiric antibiotics. Despite overlapping
clinical features, the treatment of HLH differs from systemic inﬂam-
matory response syndrome (SIRS). HLH-speciﬁc therapy is based
on the HLH-94 protocol, consisting of eight weeks of induction ther-
apy with etoposide, dexamethasone, and intrathecal methotrexate
for those patients with CNS involvement. The primary goal of this
regimen serves to suppress the fatal inﬂammatory process underly-
ing HLH. The management of SIRS differs as it primarily consists of
treatment of underlying infection if present and supportive care
(Trottestam et al., 2011).
41M. Nosratian-Baskovic et al. / Gynecologic Oncology Reports 17 (2016) 38–41While the diagnosis of HLH can be difﬁcult, the Histiocyte Society set
forth HLH-2004 diagnostic guidelines, including: 1. Fever; 2. Splenomeg-
aly; 3. Cytopenia involving at least 2 of 3 cell lineages (Hgb b 9 g/dL,
ANC b 1.0 K/μL, platelets b100 K/μL); 4. Hypertriglyceridemia (fasting
triglycerides ≥3.0 mmol/L) and/or hypoﬁbrinogenemia (ﬁbrinogen
≤1.5 g/L); 5. Hemophagocytosis (in biopsy samples of bone marrow,
spleen, or lymph nodes); 6.Low or absent natural killer cell activity; 7.
Serum ferritin ≥500 μg/L; and 8. Elevated soluble IL-2 (CD25) levels
(≥2400 U/mL or very high for age) (Henter et al., 2007). In general,
the diagnosis of HLH is supported if ﬁve of the preceding eight criteria
are satisﬁed.
Hemophagocytosis is deﬁned as the engulfment of nucleated
hematopoietic cells by activated macrophages and histiocytes as an ab-
normality in the immune regulatory system (Henter et al., 2007). Al-
though this is the hallmark histologic ﬁnding of HLH, it is not required
for diagnosis. Both ferritin and soluble IL2Rα serve asmarkers of gener-
alized inﬂammation. Elevated IL2Rα is amore speciﬁc indicator forHLH,
as it does not seem to be elevated in other processes. Ferritin is stimulat-
ed during the anti-inﬂammatory activity of macrophages in scavenging
of heme via the CD163 receptor (George, 2014). Up-regulation of CD163
on monocytes and macrophages allows for hemophagocytosis (George,
2014). In our case, both IL2Rα and ferritin levels were consistently ele-
vated preoperatively.
In malignancy-associated HLH, the HLH symptoms may precede the
diagnosis of the malignant neoplasm, occur after the diagnosis, or be-
come apparent during chemotherapy (Canna and Behrens, 2012). It
has been proposed that HLH might be initiated by the release of IFN-γ
and CD25 (alpha chain of the IL-2 receptor) from neoplastic cells, lead-
ing to signiﬁcant macrophage activation (Canna and Behrens, 2012).
IFN-γ induces the classically activated M1 pro-inﬂammatory subtype
of macrophages, in contrast to the “alternatively” activated immuno-
suppressive M2 phenotype (Vogel et al., 2014). Interestingly, IFN-γ
and macrophage colony-stimulating factor (MCSF) have both been
shown to be expressed in ovarian dysgerminomas (Suzuki et al., 1998).
In summary, we report the ﬁrst case of HLH associatedwith an ovar-
ian dysgerminoma. The incidence of HLH associated with non-
hematolymphoid malignancies is very low, but may be underestimated
given the generalized and non-speciﬁc nature of symptoms. While
there remains a great need to gain a better understanding of the disease
mechanisms of HLH, it is paramount to recognize the clinical manifesta-
tions of the disorder in order to achieve a prompt diagnosis, followed by
appropriatemanagement.Moreover, it is important to recognizeHLH asa possible secondarymanifestation or paraneoplastic syndrome of ovar-
ian pathology.
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